Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesa Laboratories (MLAB) Common Equity (2016 - 2025)

Mesa Laboratories' Common Equity history spans 15 years, with the latest figure at $186.7 million for Q4 2025.

  • For Q4 2025, Common Equity rose 20.28% year-over-year to $186.7 million; the TTM value through Dec 2025 reached $186.7 million, up 20.28%, while the annual FY2025 figure was $159.8 million, 9.93% up from the prior year.
  • Common Equity for Q4 2025 was $186.7 million at Mesa Laboratories, up from $178.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $406.2 million in Q1 2021 and bottomed at $145.4 million in Q1 2024.
  • The 5-year median for Common Equity is $383.8 million (2022), against an average of $300.9 million.
  • The largest annual shift saw Common Equity surged 84.64% in 2021 before it crashed 63.05% in 2024.
  • A 5-year view of Common Equity shows it stood at $396.3 million in 2021, then dropped by 2.3% to $387.2 million in 2022, then rose by 4.07% to $403.0 million in 2023, then tumbled by 61.48% to $155.2 million in 2024, then rose by 20.28% to $186.7 million in 2025.
  • Per Business Quant, the three most recent readings for MLAB's Common Equity are $186.7 million (Q4 2025), $178.5 million (Q3 2025), and $172.5 million (Q2 2025).